Skip to main content
. 2015 Sep 7;10:1819–1827. doi: 10.2147/COPD.S87766

Figure 1.

Figure 1

Annual rate of decline in postbronchodilator FEV1 adjusted by age, sex, height, weight, smoking status, and medication possession ratio of respiratory medications (ICS-LABA and LAMA).

Notes: (A) Among GOLD groups (A–D). (B) Among GOLD stages (I–IV).

Abbreviations: FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS-LABA, inhaled corticosteroid/long-acting β-agonist; LAMA, long-acting muscarinic antagonist.